Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 3/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.51 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453424 | 0.88 | CFTR (0.59) | CFTRFLT3RAB9ANPC1KMT2A | |
| SCHEMBL5451652 | 0.87 | CFTR (0.60) | CFTRFLT3RAB9ANPC1KMT2A | |
| SCHEMBL5466862 | 0.86 | CFTR (0.57) | CFTRFLT3RAB9ANPC1KMT2A | |
| SCHEMBL5446246 | 0.86 | FLT3 (0.73) | FLT3RXFP1RAB9AKMT2AMEN1 | |
| SCHEMBL5467205 | 0.86 | CFTR (0.56) | CFTRFLT3RAB9ANPC1KMT2A | |
| SCHEMBL5448351 | 0.85 | CFTR (0.55) | CFTRRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL5457654 | 0.85 | CFTR (0.55) | CFTRFLT3RAB9ANPC1KMT2A | |
| SCHEMBL5454365 | 0.85 | CFTR (0.55) | CFTRRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL5458044 | 0.85 | CFTR (0.57) | CFTRRAB9ANPC1KMT2AMEN1 | |
| SCHEMBL5449672 | 0.85 | CFTR (0.55) | CFTRRAB9ANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | CFTR 2030/4885FLT3 3509/4885RXFP1 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.